News
MIRM
123.77
+5.53%
6.49
Weekly Report: what happened at MIRM last week (0615-0619)?
Weekly Report · 6d ago
Mirum SVP, Global Controller Jolanda Howe sells 2,594 shares for $264,458.3
PUBT · 06/18 22:40
Mirum Shareholders Approve Directors, Auditors and Compensation
TipRanks · 06/18 21:01
Mirum Pharmaceuticals holds annual shareholder meeting
PUBT · 06/18 20:06
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
NASDAQ · 06/17 10:47
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
NASDAQ · 06/16 07:55
Mirum Pharmaceuticals Is Maintained at Market Outperform by Citizens
Dow Jones · 06/15 14:16
Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Raises Price Target to $146
Benzinga · 06/15 14:06
Mirum Therapeutics: Strong FOP Data and Priority Review Support Buy Rating and Unchanged $150 Price Target
TipRanks · 06/15 11:55
Buy Rating Reiterated on Mirum Pharmaceuticals as Zilurgisertib Data De-Risk Pipeline; $145 Price Target Unchanged with ~46% Upside Potential
TipRanks · 06/15 10:45
Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX), Celldex (CLDX) and Mirum Pharmaceuticals (MIRM)
TipRanks · 06/15 10:40
Weekly Report: what happened at MIRM last week (0608-0612)?
Weekly Report · 06/15 10:38
Mirum Pharmaceuticals price target raised to $146 from $140 at Citizens
TipRanks · 06/15 09:55
Reported Sunday, Mirum Pharmaceuticals And Incyte Report Pivotal Phase 2 PROGRESS Study Results For Zilurgisertib Showing 99.9% Reduction In New HO Lesion Volume In Fibrodysplasia Ossificans Progressiva Patients At Week 24
Benzinga · 06/15 06:53
Mirum and Incyte's zilurgisertib shows positive Phase 2 data in FOP
Seeking Alpha · 06/15 06:38
Mirum's Zilurgisertib Delivers Strong Phase 2 Cohort 1 Data In FOP Ahead Of FDA Decision
NASDAQ · 06/15 05:20
Incyte, Mirum announces Phase 2 results from Cohort 1 of Progress study
TipRanks · 06/14 21:20
Mirum, Incyte report pivotal Phase 2 PROGRESS data showing zilurgisertib cuts new FOP bone lesion volume 99.9% at Week 24
PUBT · 06/14 20:35
MIRUM PHARMACEUTICALS AND INCYTE ANNOUNCE POSITIVE PIVOTAL PHASE 2 RESULTS FROM PROGRESS STUDY OF ZILURGISERTIB IN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
Reuters · 06/14 20:35
Mirum grants inducement equity awards to 8 new hires, sets options at $94 per share
PUBT · 06/11 20:01
More
Webull provides a variety of real-time MIRM stock news. You can receive the latest news about Mirum Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About MIRM
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States, Canada and Japan. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.